Alpha Emitter Market Synopsis:
Alpha Emitter Market Size Was Valued at USD 1.30 Billion in 2023, and is Projected to Reach USD 3.09 Billion by 2032, Growing at a CAGR of 10.10% From 2024-2032.
Alpha Emitter Market can be defined as the business of manufacturing and applying alpha-emitting radioisotopes in treatments like cancer, nuclear, and radiation treatment. These emitters include radium–223, actinium–225, thorium–227, bismuth–213 and others and have high activity and are widely used in targeted radiotherapy especially in oncology. It also extends the application of these emitters in the research and diagnosis market with technical advancements aiming at higher effectiveness and lower risks.
- One of the factors that are pushing the growth of the Market is the increasing rate of cancer, especially in the developed countries. The desire and hence the request for enhanced cancer therapies such as targeted treatments have over time created a trend towards the use of alpha-emitting radionuclides. Praise for alpha emitters is high as these agents have proved to be efficient when used to treat certain cancers such as prostate cancer Therefore, their use in clinical practice is on the rise, thus driving the market forward.
- Another factor motivating this work is the constant innovations in the field of nuclear medicine. The application of the alpha emitters in the radiopharmaceuticals has gradually intensified because of its potential to deposit high doses of energy in the pathological tissue while sparing the adjacent normal tissues. Consequently, market growth is driven by an increase in research activities directed at enhancing the efficacy of alpha particle therapy.
Alpha Emitter Market Trend Analysis:
Targeted alpha therapy
- A major trend identified in the Alpha Emitter Market is targeted alpha therapy, which entails accurate positioning of radiation in tumor tissues. TAT has been established as a potentially effective radiation substitute because it focuses on engulphing malignant tissue and destroying cancer cells. This is even made possible by the progression of radiopharmaceutical research and trials which are exposing the capability of alpha-emitting nuclides.
- The next trend is an increased focus on integrating the alpha emitters with other kinds of cancer treatments like immunotherapy and chemotherapy in the overall therapeutic orientation. This combination therapy is gradually becoming popular since it enables growth of a more effective treatment plan as it tackles the cancer cells from various angles, hence giving patients with otherwise hard to manage cancers some hope.
Concentrated in nuclear medicine and research
- There is a great opportunity for the growth of the Alpha Emitter Market; however, it remains almost unexplored in terms of new applications, especially concentrated in nuclear medicine and research. Thus, the prospects in this case are rather great with the further development of the use of alpha emitters in areas such as immunomodulation or the targeted signal of specific markers of malignant neoplasms. Therefore, in the future the number of clinical trials may increase resulting in development of new therapy options for different types of cancer and other diseases that is good for all the participants of the market.
- Moreover, growth of the health care sector infrastructure and improving reach in developing countries is a great opportunity for the Alpha Emitter Market. Asian-Pacific, Latin American countries and several African nations are increasingly focusing on enhancing the standards of their health care that include cancer care centres. This increasing infrastructure along with the increasing awareness of specialized cancer therapies global provides the right circumstances adopted of alpha emitters in these markets as a promising revenue-generating opportunity.
Alpha Emitter Market Segment Analysis:
Alpha Emitter Market Segmented on the basis of Type, Application End-User, and Region.
By Type, Radium-223 segment is expected to dominate the market during the forecast period
- The alpha emitter market is the big genre that contains Radium-223, Actinium-225, Thorium-227, Bismuth-213 and other alpha emitters. The most commonly used radioactive agent to treat prostate cancer with bone metastases is Radium-223 and Actinium-225 has been used in target treatment of several cancer including leukemia. Thorium-227 and Bismuth-213 are also used in research related to cancer therapy. These emitters can be incorporated into therapy development schemes since all of them have distinct characteristics in relation to their emission activity and the resultant therapeutic effects.
By Application, Cancer Therapy segment expected to held the largest share
- The By Application segment of the Alpha Emitter Market consists of Cancer Therapy, Nuclear Medicine, Radiation Therapy and other specialised purposes. Cancer therapy is the most important application since radiation using alpha emitters is expanding rapidly in the field of oncology. In nuclear medicine alpha sources are employed in images and diagnostic measures, but radiation treatment makes use of alpha particles as therapy. Additional uses of alpha emitters are seen in research and in furthering drug advancements for diseases, not limited to cancer, to be treated by this element.
Alpha Emitter Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast period
- North America continues to lead the Alpha Emitter Market because of factors such as well-developed healthcare systems, emphasis on research and development and a larger patient pool of cancer. In this regard, America is most advanced particularly with TAT therapy –Targeted Alpha Therapy – and constitutes home to several leading players who are interested in the development and commercialization of alpha emitters. Not only this, the existence of favorable regulation and policies related to radiopharmaceuticals and the presence of major players in the pharmaceutical and biotechnological industry make North America a formidable market.
Active Key Players in the Alpha Emitter Market:
- Actinium Pharmaceuticals (USA)
- Alpha Tau Medical (Israel)
- Bayer AG (Germany)
- Endocyte Inc. (USA)
- Immunomedics (USA)
- Ipsen (France)
- Novartis (Switzerland)
- Progenics Pharmaceuticals (USA)
- Qview Medical (USA)
- Radiopharm Theranostics (Australia)
- Other key Players, and other Active Players
Recent Development in the Alpha Emitter Market:
- In January 2023, Orano Med, a pharmaceutical company, disclosed that it had administered the first dose of 212Pb-GRPR in a Phase 1 clinical trial. 212Pb-GRPR is an alpha radioligand therapy featuring lead-212, designed for patients with solid tumors that exhibit the gastrin-releasing peptide receptor.
Alpha Emitter Market Scope:
|
Global Alpha Emitter Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 1.30 Billion |
|
Forecast Period 2024-32 CAGR: |
10.10% |
Market Size in 2032: |
USD 3.09 Billion |
|
Segments Covered: |
By Type |
|
|
|
By Application |
|
||
|
By End-User |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Alpha Emitter Market by Type (2018-2032)
4.1 Alpha Emitter Market Snapshot and Growth Engine
4.2 Market Overview
4.3 Radium-223
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
4.3.3 Key Market Trends, Growth Factors, and Opportunities
4.3.4 Geographic Segmentation Analysis
4.4 Actinium-225
4.5 Thorium-227
4.6 Bismuth-213
4.7 Other Alpha Emitters
Chapter 5: Alpha Emitter Market by Application (2018-2032)
5.1 Alpha Emitter Market Snapshot and Growth Engine
5.2 Market Overview
5.3 Cancer Therapy
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
5.3.3 Key Market Trends, Growth Factors, and Opportunities
5.3.4 Geographic Segmentation Analysis
5.4 Nuclear Medicine
5.5 Radiation Therapy
5.6 Others
Chapter 6: Alpha Emitter Market by End-User (2018-2032)
6.1 Alpha Emitter Market Snapshot and Growth Engine
6.2 Market Overview
6.3 Hospitals
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
6.3.3 Key Market Trends, Growth Factors, and Opportunities
6.3.4 Geographic Segmentation Analysis
6.4 Research Institutes
6.5 Diagnostic Laboratories
6.6 Others
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Benchmarking
7.1.2 Alpha Emitter Market Share by Manufacturer (2024)
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Mergers and Acquisitions
7.2 BAYER AG (GERMANY)
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Role of the Company in the Market
7.2.5 Sustainability and Social Responsibility
7.2.6 Operating Business Segments
7.2.7 Product Portfolio
7.2.8 Business Performance
7.2.9 Key Strategic Moves and Recent Developments
7.2.10 SWOT Analysis
7.3 NOVARTIS (SWITZERLAND)
7.4 ACTINIUM PHARMACEUTICALS (USA)
7.5 ALPHA TAU MEDICAL (ISRAEL)
7.6 PROGENICS PHARMACEUTICALS (USA)
7.7 IMMUNOMEDICS (USA)
7.8 ENDOCYTE INC. (USA)
7.9 IPSEN (FRANCE)
7.10 RADIOPHARM THERANOSTICS (AUSTRALIA)
7.11 QVIEW MEDICAL (USA)
7.12 OTHER ACTIVE PLAYERS
Chapter 8: Global Alpha Emitter Market By Region
8.1 Overview
8.2. North America Alpha Emitter Market
8.2.1 Key Market Trends, Growth Factors and Opportunities
8.2.2 Top Key Companies
8.2.3 Historic and Forecasted Market Size by Segments
8.2.4 Historic and Forecasted Market Size by Type
8.2.4.1 Radium-223
8.2.4.2 Actinium-225
8.2.4.3 Thorium-227
8.2.4.4 Bismuth-213
8.2.4.5 Other Alpha Emitters
8.2.5 Historic and Forecasted Market Size by Application
8.2.5.1 Cancer Therapy
8.2.5.2 Nuclear Medicine
8.2.5.3 Radiation Therapy
8.2.5.4 Others
8.2.6 Historic and Forecasted Market Size by End-User
8.2.6.1 Hospitals
8.2.6.2 Research Institutes
8.2.6.3 Diagnostic Laboratories
8.2.6.4 Others
8.2.7 Historic and Forecast Market Size by Country
8.2.7.1 US
8.2.7.2 Canada
8.2.7.3 Mexico
8.3. Eastern Europe Alpha Emitter Market
8.3.1 Key Market Trends, Growth Factors and Opportunities
8.3.2 Top Key Companies
8.3.3 Historic and Forecasted Market Size by Segments
8.3.4 Historic and Forecasted Market Size by Type
8.3.4.1 Radium-223
8.3.4.2 Actinium-225
8.3.4.3 Thorium-227
8.3.4.4 Bismuth-213
8.3.4.5 Other Alpha Emitters
8.3.5 Historic and Forecasted Market Size by Application
8.3.5.1 Cancer Therapy
8.3.5.2 Nuclear Medicine
8.3.5.3 Radiation Therapy
8.3.5.4 Others
8.3.6 Historic and Forecasted Market Size by End-User
8.3.6.1 Hospitals
8.3.6.2 Research Institutes
8.3.6.3 Diagnostic Laboratories
8.3.6.4 Others
8.3.7 Historic and Forecast Market Size by Country
8.3.7.1 Russia
8.3.7.2 Bulgaria
8.3.7.3 The Czech Republic
8.3.7.4 Hungary
8.3.7.5 Poland
8.3.7.6 Romania
8.3.7.7 Rest of Eastern Europe
8.4. Western Europe Alpha Emitter Market
8.4.1 Key Market Trends, Growth Factors and Opportunities
8.4.2 Top Key Companies
8.4.3 Historic and Forecasted Market Size by Segments
8.4.4 Historic and Forecasted Market Size by Type
8.4.4.1 Radium-223
8.4.4.2 Actinium-225
8.4.4.3 Thorium-227
8.4.4.4 Bismuth-213
8.4.4.5 Other Alpha Emitters
8.4.5 Historic and Forecasted Market Size by Application
8.4.5.1 Cancer Therapy
8.4.5.2 Nuclear Medicine
8.4.5.3 Radiation Therapy
8.4.5.4 Others
8.4.6 Historic and Forecasted Market Size by End-User
8.4.6.1 Hospitals
8.4.6.2 Research Institutes
8.4.6.3 Diagnostic Laboratories
8.4.6.4 Others
8.4.7 Historic and Forecast Market Size by Country
8.4.7.1 Germany
8.4.7.2 UK
8.4.7.3 France
8.4.7.4 The Netherlands
8.4.7.5 Italy
8.4.7.6 Spain
8.4.7.7 Rest of Western Europe
8.5. Asia Pacific Alpha Emitter Market
8.5.1 Key Market Trends, Growth Factors and Opportunities
8.5.2 Top Key Companies
8.5.3 Historic and Forecasted Market Size by Segments
8.5.4 Historic and Forecasted Market Size by Type
8.5.4.1 Radium-223
8.5.4.2 Actinium-225
8.5.4.3 Thorium-227
8.5.4.4 Bismuth-213
8.5.4.5 Other Alpha Emitters
8.5.5 Historic and Forecasted Market Size by Application
8.5.5.1 Cancer Therapy
8.5.5.2 Nuclear Medicine
8.5.5.3 Radiation Therapy
8.5.5.4 Others
8.5.6 Historic and Forecasted Market Size by End-User
8.5.6.1 Hospitals
8.5.6.2 Research Institutes
8.5.6.3 Diagnostic Laboratories
8.5.6.4 Others
8.5.7 Historic and Forecast Market Size by Country
8.5.7.1 China
8.5.7.2 India
8.5.7.3 Japan
8.5.7.4 South Korea
8.5.7.5 Malaysia
8.5.7.6 Thailand
8.5.7.7 Vietnam
8.5.7.8 The Philippines
8.5.7.9 Australia
8.5.7.10 New Zealand
8.5.7.11 Rest of APAC
8.6. Middle East & Africa Alpha Emitter Market
8.6.1 Key Market Trends, Growth Factors and Opportunities
8.6.2 Top Key Companies
8.6.3 Historic and Forecasted Market Size by Segments
8.6.4 Historic and Forecasted Market Size by Type
8.6.4.1 Radium-223
8.6.4.2 Actinium-225
8.6.4.3 Thorium-227
8.6.4.4 Bismuth-213
8.6.4.5 Other Alpha Emitters
8.6.5 Historic and Forecasted Market Size by Application
8.6.5.1 Cancer Therapy
8.6.5.2 Nuclear Medicine
8.6.5.3 Radiation Therapy
8.6.5.4 Others
8.6.6 Historic and Forecasted Market Size by End-User
8.6.6.1 Hospitals
8.6.6.2 Research Institutes
8.6.6.3 Diagnostic Laboratories
8.6.6.4 Others
8.6.7 Historic and Forecast Market Size by Country
8.6.7.1 Turkiye
8.6.7.2 Bahrain
8.6.7.3 Kuwait
8.6.7.4 Saudi Arabia
8.6.7.5 Qatar
8.6.7.6 UAE
8.6.7.7 Israel
8.6.7.8 South Africa
8.7. South America Alpha Emitter Market
8.7.1 Key Market Trends, Growth Factors and Opportunities
8.7.2 Top Key Companies
8.7.3 Historic and Forecasted Market Size by Segments
8.7.4 Historic and Forecasted Market Size by Type
8.7.4.1 Radium-223
8.7.4.2 Actinium-225
8.7.4.3 Thorium-227
8.7.4.4 Bismuth-213
8.7.4.5 Other Alpha Emitters
8.7.5 Historic and Forecasted Market Size by Application
8.7.5.1 Cancer Therapy
8.7.5.2 Nuclear Medicine
8.7.5.3 Radiation Therapy
8.7.5.4 Others
8.7.6 Historic and Forecasted Market Size by End-User
8.7.6.1 Hospitals
8.7.6.2 Research Institutes
8.7.6.3 Diagnostic Laboratories
8.7.6.4 Others
8.7.7 Historic and Forecast Market Size by Country
8.7.7.1 Brazil
8.7.7.2 Argentina
8.7.7.3 Rest of SA
Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies
Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Alpha Emitter Market by Type (2018-2032)
4.1 Alpha Emitter Market Snapshot and Growth Engine
4.2 Market Overview
4.3 Radium-223
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
4.3.3 Key Market Trends, Growth Factors, and Opportunities
4.3.4 Geographic Segmentation Analysis
4.4 Actinium-225
4.5 Thorium-227
4.6 Bismuth-213
4.7 Other Alpha Emitters
Chapter 5: Alpha Emitter Market by Application (2018-2032)
5.1 Alpha Emitter Market Snapshot and Growth Engine
5.2 Market Overview
5.3 Cancer Therapy
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
5.3.3 Key Market Trends, Growth Factors, and Opportunities
5.3.4 Geographic Segmentation Analysis
5.4 Nuclear Medicine
5.5 Radiation Therapy
5.6 Others
Chapter 6: Alpha Emitter Market by End-User (2018-2032)
6.1 Alpha Emitter Market Snapshot and Growth Engine
6.2 Market Overview
6.3 Hospitals
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
6.3.3 Key Market Trends, Growth Factors, and Opportunities
6.3.4 Geographic Segmentation Analysis
6.4 Research Institutes
6.5 Diagnostic Laboratories
6.6 Others
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Benchmarking
7.1.2 Alpha Emitter Market Share by Manufacturer (2024)
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Mergers and Acquisitions
7.2 BAYER AG (GERMANY)
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Role of the Company in the Market
7.2.5 Sustainability and Social Responsibility
7.2.6 Operating Business Segments
7.2.7 Product Portfolio
7.2.8 Business Performance
7.2.9 Key Strategic Moves and Recent Developments
7.2.10 SWOT Analysis
7.3 NOVARTIS (SWITZERLAND)
7.4 ACTINIUM PHARMACEUTICALS (USA)
7.5 ALPHA TAU MEDICAL (ISRAEL)
7.6 PROGENICS PHARMACEUTICALS (USA)
7.7 IMMUNOMEDICS (USA)
7.8 ENDOCYTE INC. (USA)
7.9 IPSEN (FRANCE)
7.10 RADIOPHARM THERANOSTICS (AUSTRALIA)
7.11 QVIEW MEDICAL (USA)
7.12 OTHER ACTIVE PLAYERS
Chapter 8: Global Alpha Emitter Market By Region
8.1 Overview
8.2. North America Alpha Emitter Market
8.2.1 Key Market Trends, Growth Factors and Opportunities
8.2.2 Top Key Companies
8.2.3 Historic and Forecasted Market Size by Segments
8.2.4 Historic and Forecasted Market Size by Type
8.2.4.1 Radium-223
8.2.4.2 Actinium-225
8.2.4.3 Thorium-227
8.2.4.4 Bismuth-213
8.2.4.5 Other Alpha Emitters
8.2.5 Historic and Forecasted Market Size by Application
8.2.5.1 Cancer Therapy
8.2.5.2 Nuclear Medicine
8.2.5.3 Radiation Therapy
8.2.5.4 Others
8.2.6 Historic and Forecasted Market Size by End-User
8.2.6.1 Hospitals
8.2.6.2 Research Institutes
8.2.6.3 Diagnostic Laboratories
8.2.6.4 Others
8.2.7 Historic and Forecast Market Size by Country
8.2.7.1 US
8.2.7.2 Canada
8.2.7.3 Mexico
8.3. Eastern Europe Alpha Emitter Market
8.3.1 Key Market Trends, Growth Factors and Opportunities
8.3.2 Top Key Companies
8.3.3 Historic and Forecasted Market Size by Segments
8.3.4 Historic and Forecasted Market Size by Type
8.3.4.1 Radium-223
8.3.4.2 Actinium-225
8.3.4.3 Thorium-227
8.3.4.4 Bismuth-213
8.3.4.5 Other Alpha Emitters
8.3.5 Historic and Forecasted Market Size by Application
8.3.5.1 Cancer Therapy
8.3.5.2 Nuclear Medicine
8.3.5.3 Radiation Therapy
8.3.5.4 Others
8.3.6 Historic and Forecasted Market Size by End-User
8.3.6.1 Hospitals
8.3.6.2 Research Institutes
8.3.6.3 Diagnostic Laboratories
8.3.6.4 Others
8.3.7 Historic and Forecast Market Size by Country
8.3.7.1 Russia
8.3.7.2 Bulgaria
8.3.7.3 The Czech Republic
8.3.7.4 Hungary
8.3.7.5 Poland
8.3.7.6 Romania
8.3.7.7 Rest of Eastern Europe
8.4. Western Europe Alpha Emitter Market
8.4.1 Key Market Trends, Growth Factors and Opportunities
8.4.2 Top Key Companies
8.4.3 Historic and Forecasted Market Size by Segments
8.4.4 Historic and Forecasted Market Size by Type
8.4.4.1 Radium-223
8.4.4.2 Actinium-225
8.4.4.3 Thorium-227
8.4.4.4 Bismuth-213
8.4.4.5 Other Alpha Emitters
8.4.5 Historic and Forecasted Market Size by Application
8.4.5.1 Cancer Therapy
8.4.5.2 Nuclear Medicine
8.4.5.3 Radiation Therapy
8.4.5.4 Others
8.4.6 Historic and Forecasted Market Size by End-User
8.4.6.1 Hospitals
8.4.6.2 Research Institutes
8.4.6.3 Diagnostic Laboratories
8.4.6.4 Others
8.4.7 Historic and Forecast Market Size by Country
8.4.7.1 Germany
8.4.7.2 UK
8.4.7.3 France
8.4.7.4 The Netherlands
8.4.7.5 Italy
8.4.7.6 Spain
8.4.7.7 Rest of Western Europe
8.5. Asia Pacific Alpha Emitter Market
8.5.1 Key Market Trends, Growth Factors and Opportunities
8.5.2 Top Key Companies
8.5.3 Historic and Forecasted Market Size by Segments
8.5.4 Historic and Forecasted Market Size by Type
8.5.4.1 Radium-223
8.5.4.2 Actinium-225
8.5.4.3 Thorium-227
8.5.4.4 Bismuth-213
8.5.4.5 Other Alpha Emitters
8.5.5 Historic and Forecasted Market Size by Application
8.5.5.1 Cancer Therapy
8.5.5.2 Nuclear Medicine
8.5.5.3 Radiation Therapy
8.5.5.4 Others
8.5.6 Historic and Forecasted Market Size by End-User
8.5.6.1 Hospitals
8.5.6.2 Research Institutes
8.5.6.3 Diagnostic Laboratories
8.5.6.4 Others
8.5.7 Historic and Forecast Market Size by Country
8.5.7.1 China
8.5.7.2 India
8.5.7.3 Japan
8.5.7.4 South Korea
8.5.7.5 Malaysia
8.5.7.6 Thailand
8.5.7.7 Vietnam
8.5.7.8 The Philippines
8.5.7.9 Australia
8.5.7.10 New Zealand
8.5.7.11 Rest of APAC
8.6. Middle East & Africa Alpha Emitter Market
8.6.1 Key Market Trends, Growth Factors and Opportunities
8.6.2 Top Key Companies
8.6.3 Historic and Forecasted Market Size by Segments
8.6.4 Historic and Forecasted Market Size by Type
8.6.4.1 Radium-223
8.6.4.2 Actinium-225
8.6.4.3 Thorium-227
8.6.4.4 Bismuth-213
8.6.4.5 Other Alpha Emitters
8.6.5 Historic and Forecasted Market Size by Application
8.6.5.1 Cancer Therapy
8.6.5.2 Nuclear Medicine
8.6.5.3 Radiation Therapy
8.6.5.4 Others
8.6.6 Historic and Forecasted Market Size by End-User
8.6.6.1 Hospitals
8.6.6.2 Research Institutes
8.6.6.3 Diagnostic Laboratories
8.6.6.4 Others
8.6.7 Historic and Forecast Market Size by Country
8.6.7.1 Turkiye
8.6.7.2 Bahrain
8.6.7.3 Kuwait
8.6.7.4 Saudi Arabia
8.6.7.5 Qatar
8.6.7.6 UAE
8.6.7.7 Israel
8.6.7.8 South Africa
8.7. South America Alpha Emitter Market
8.7.1 Key Market Trends, Growth Factors and Opportunities
8.7.2 Top Key Companies
8.7.3 Historic and Forecasted Market Size by Segments
8.7.4 Historic and Forecasted Market Size by Type
8.7.4.1 Radium-223
8.7.4.2 Actinium-225
8.7.4.3 Thorium-227
8.7.4.4 Bismuth-213
8.7.4.5 Other Alpha Emitters
8.7.5 Historic and Forecasted Market Size by Application
8.7.5.1 Cancer Therapy
8.7.5.2 Nuclear Medicine
8.7.5.3 Radiation Therapy
8.7.5.4 Others
8.7.6 Historic and Forecasted Market Size by End-User
8.7.6.1 Hospitals
8.7.6.2 Research Institutes
8.7.6.3 Diagnostic Laboratories
8.7.6.4 Others
8.7.7 Historic and Forecast Market Size by Country
8.7.7.1 Brazil
8.7.7.2 Argentina
8.7.7.3 Rest of SA
Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies
Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research
Alpha Emitter Market Scope:
|
Global Alpha Emitter Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 1.30 Billion |
|
Forecast Period 2024-32 CAGR: |
10.10% |
Market Size in 2032: |
USD 3.09 Billion |
|
Segments Covered: |
By Type |
|
|
|
By Application |
|
||
|
By End-User |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
Frequently Asked Questions :
What would be the forecast period in the Alpha Emitter Market research report?
The forecast period in the Alpha Emitter Market research report is 2024-2032.
Who are the key players in the Alpha Emitter Market?
Bayer AG (Germany), Novartis (Switzerland), Actinium Pharmaceuticals (USA), Alpha Tau Medical (Israel), Progenics Pharmaceuticals (USA), Immunomedics (USA), Endocyte Inc. (USA), Ipsen (France), Radiopharm Theranostics (Australia), Qview Medical (USA) and other Active Players.
What are the segments of the Alpha Emitter Market?
The Alpha Emitter Market is segmented into By Type, By Application, By End-User and region. By Type, the market is categorized into Radium-223, Actinium-225, Thorium-227, Bismuth-213, Other Alpha Emitters. By Application, the market is categorized into Cancer Therapy, Nuclear Medicine, Radiation Therapy, Others. By End-User, the market is categorized into Hospitals, Research Institutes, Diagnostic Laboratories, Others. By region, it is analyzed across North America (U.S.; Canada; Mexico), Eastern Europe (Bulgaria; The Czech Republic; Hungary; Poland; Romania; Rest of Eastern Europe), Western Europe (Germany; UK; France; Netherlands; Italy; Russia; Spain; Rest of Western Europe), Asia-Pacific (China; India; Japan; Southeast Asia, etc.), South America (Brazil; Argentina, etc.), Middle East & Africa (Saudi Arabia; South Africa, etc.).
What is the Alpha Emitter Market?
Alpha Emitter Market can be defined as the business of manufacturing and applying alpha-emitting radioisotopes in treatments like cancer, nuclear, and radiation treatment. These emitters include radium–223, actinium–225, thorium–227, bismuth–213 and others and have high activity and are widely used in targeted radiotherapy especially in oncology. It also extends the application of these emitters in the research and diagnosis market with technical advancements aiming at higher effectiveness and lower risks.
How big is the Alpha Emitter Market?
Alpha Emitter Market Size Was Valued at USD 1.30 Billion in 2023, and is Projected to Reach USD 3.09 Billion by 2032, Growing at a CAGR of 10.10% From 2024-2032.
